MedPageToday
MedPage Today) — Tofacitinib (Xeljanz) may be a viable option for patients with ulcerative colitis (UC) who have failed multiple biologic therapies, a French multicenter, real-world study suggested.
Among patients previously treated with at…
Read More
JAK Inhibitor May Be Best Bet for UC Patients Who Fail Multiple Biologics
MedPage Today) — Tofacitinib (Xeljanz) may be a viable option for patients with ulcerative colitis (UC) who have failed multiple biologic therapies, a French multicenter, real-world study suggested. Among patients previously treated with at…